



Shilpa Medicare Limited

Corporate & Admin Office:

"Shilpa House", # 12-6-214/A-1, Hyderabad Road,
Raichur – 584 135, Karnataka, India
Tel: +91-8532-238704, Fax: +91-8532-238876
Email: info@vbshilpa.com, Web: www.vbshilpa.com
CIN: L85110KA1987PLC008739

Date: 03 August 2026

To

Corporate Relationship Department,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai-400 001

National Stock Exchange of India Ltd.
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block
Bandra Kurla Complex, Bandra (E)
Mumbai-400 051

Stock Code: NSE: SHILPAMED/BSE-530549

Dear Sir/Madam,

Sub: Appointment of Dr. Uday N. Harle as Chief Executive Officer (CEO) of Shilpa Biologicals Private Limited.

Ref: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform that Dr. Uday N. Harle has been appointed as the Chief Executive Officer (CEO) - **Shilpa Biologicals Private Limited, a Wholly Owned Subsidiary of Shilpa Medicare Limited** (Senior Managerial Personnel) of the Company with effect from 03 August 2026.

The requisite details as prescribed under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Master Circular No. HO/49/14/14(7)2025-CFDPOD2/I/3762/2026 dated 30th January 2026, are enclosed herewith as **Annexure A**.

This is for your information and records.

For SHILPA MEDICARE LIMITED

Ritu Tiwary
Company Secretary & Compliance Officer

Disclosure of events and information pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Master Circular No. HO/49/14/14(7)2025-CFDPD2/I/3762/2026 dated 30th January 2026.

Annexure A

Name of Director / Senior Managerial Personnel	Dr. Uday N. Harle
Designation of Director / Senior Managerial Personnel	Chief Executive Officer (CEO) - Shilpa Biologicals Private Limited
Reason for Change viz. appointment, reappointment, resignation, removal, death or otherwise	Appointment of Dr. Uday N. Harle as Chief Executive Officer (CEO) of Shilpa Biologicals Private Limited, a wholly owned subsidiary of Shilpa Medicare Limited.
Date of Appointment/ reappointment / cessation -(as applicable)	03 August 2026
Term of appointment / reappointment	Not Applicable
Brief Profile (in case of appointment)	Dr. Uday N. Harle holds a Ph.D. in Pharmaceutical Sciences from Nagpur University (RTM Nagpur University) and a Master of Science in Pharmacy. He also holds Post-Graduate Diplomas in Business Management and Marketing Management from IGNOU. Dr. Harle brings approximately 24 years of experience in the global biopharmaceutical industry, including over 18 years of experience in biologics and biosimilars and more than 14 years in leadership roles across research and development, clinical development, regulatory affairs, manufacturing, commercialization, and business management. His recent assignment was as a Chief Business Officer at Artemis Medicare Services Limited and Premedium Pharma (Apollo Group). Prior to this, he served as Assistant Vice President & Global Head - Clinical Development at Amneal Group / Kashiv Biosciences, Global Head - Clinical Development at Abbott and Associate Director & R&D Head at Ferring Pharmaceuticals. He has also held key positions with Bharat Serums & Vaccines, Sun Pharma and other leading pharmaceutical organizations. His expertise spans the entire biologics value chain, including portfolio strategy, research and development, CMC, clinical development, regulatory approvals, manufacturing, commercialization, CDMO partnerships, and P&L management. He has extensive experience across biosimilars, novel biologics,



Innovating for
affordable healthcare

Shilpa Medicare Limited

Corporate & Admin Office:

"Shilpa House", # 12-6-214/A-1, Hyderabad Road,
Raichur – 584 135, Karnataka, India

Tel: +91-8532-238704, Fax: +91-8532-238876

Email: info@vbshilpa.com, Web: www.vbshilpa.com

CIN: L85110KA1987PLC008739

peptides, recombinant proteins, cell therapies (including CAR-T) and medical devices.

Dr. Harle possesses significant global regulatory experience, having worked extensively with regulatory agencies including the USFDA, EMA, MHRA, Health Canada, and CDSCO. He has contributed to the development of more than 10 biosimilars and over 5 novel biologics, including multiple IND and BLA submissions.

He has authored approximately 40 scientific publications, published 2 books and holds 2 patents. He has also received several industry awards recognizing his contributions and excellence in biopharmaceutical research and development.